Overview

Detailed Summary

Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs).
In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid.
The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability.
Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products.
Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
Market Cap: 1,08,978 Cr
Volatility: Low Risk
P/E Ratio: 22.9
Industry P/E: 26.5
PEG Ratio: 2.5
P/B Ratio: 3.3
52W High: 1,672.20
52W Low: 1,283.00

Sales CAGR

1Y: 6.88%
3Y: 7.38%
5Y: 8.51%
10Y: 5.15%

Profit CAGR

1Y: 27.33%
3Y: 21.40%
5Y: 17.34%
10Y: 15.03%

ROE

TTM: 16.53%
3Y: 14.91%
5Y: 14.09%
10Y: 12.46%

ROCE

TTM: 21.05%
3Y: 20.09%
5Y: 18.88%
10Y: 15.55%

Technicals

‌

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
CIPLA	1348.00	1,08,978 Cr	22.90	3.31	1.19	16.53	21.05	11.32
DRREDDY	1283.00	1,06,904 Cr	19.23	2.97	0.62	16.03	18.66	10.16
LUPIN	2223.80	1,01,749 Cr	20.43	5.18	0.54	22.03	21.92	13.94
ZYDUSLIFE	910.05	91,572 Cr	17.91	3.62	1.21	19.44	19.08	10.52
MANKIND	2072.00	85,665 Cr	46.03	5.60	0.00	11.45	12.34	6.26
AUROPHARMA	1171.20	67,358 Cr	19.26	1.92	0.00	9.77	12.69	6.63
ALKEM	5463.60	65,331 Cr	27.20	4.90	0.82	17.69	18.13	11.95

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	6,678	6,604	6,163	6,694	7,051	7,073	6,730	6,957	7,589	7,074
Expenses	4,944	4,856	4,847	4,978	5,165	5,084	5,192	5,179	5,695	5,819
Operating Profit	1,734	1,748	1,316	1,716	1,886	1,989	1,538	1,778	1,895	1,255
OPM %	25.96	26.46	21.35	25.63	26.74	28.12	22.85	25.56	24.97	17.74
Other Income	176	-10	249	160	191	222	289	259	269	-70
Interest	26	30	18	18	15	15	14	14	13	14
Depreciation	290	233	288	247	272	280	309	253	297	278
Profit Before Tax	1,594	1,474	1,259	1,611	1,789	1,916	1,504	1,770	1,854	893
Tax %	27.50	27.50	25.80	27.00	27.00	17.35	18.57	27.00	27.00	24.47
Net Profit	1,156	1,069	934	1,176	1,306	1,584	1,225	1,292	1,353	675
EPS in Rs	13.99	13.06	11.61	14.58	16.12	19.43	15.12	16.06	16.72	8.36

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	14,630	15,219	16,362	17,132	19,160	21,763	22,753	25,774	27,548	27,811
Expenses	11,919	12,329	13,265	13,926	14,907	17,211	17,726	19,483	20,420	20,621
Operating Profit	2,712	2,890	3,097	3,206	4,252	4,553	5,027	6,291	7,128	7,190
OPM %	18.54	18.99	18.93	18.71	22.19	20.92	22.09	24.41	25.87	25.85
Other Income	229	280	477	344	266	99	293	552	862	960
Interest	159	114	168	197	161	106	110	90	62	58
Depreciation	1,323	1,323	1,326	1,175	1,068	1,052	1,172	1,051	1,107	1,113
Profit Before Tax	1,222	1,669	2,079	2,178	3,290	3,493	4,038	5,702	6,821	6,979
Tax %	14.71	14.98	27.39	28.98	27.01	26.73	29.79	27.12	22.43	22.53
Net Profit	1,042	1,419	1,510	1,547	2,401	2,559	2,835	4,155	5,291	5,407
EPS in Rs	12.43	17.44	18.88	19.13	29.73	31.11	34.67	50.99	65.23	56.26
Dividend Payout %	16.00	17.14	15.85	20.88	16.78	16.04	24.50	25.49	24.52	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	161	161	161	161	161	161	161	161	161	162
Reserves	11,356	12,383	14,068	14,851	15,602	18,165	20,680	23,246	26,545	31,032
Borrowings	5,192	4,113	4,098	4,316	2,816	2,014	1,056	803	559	438
Other Liabilities	4,420	4,381	4,533	4,635	5,083	4,811	5,204	5,252	5,452	5,755
Total Liabilities	21,128	21,037	22,861	23,963	23,663	25,152	27,101	29,463	32,718	37,387
Fixed Assets	9,368	9,490	9,949	9,547	9,559	9,394	9,622	9,101	9,494	9,895
CWIP	2,061	1,683	981	676	825	969	766	1,093	1,153	1,566
Investments	759	975	1,260	2,616	1,595	2,832	2,612	3,722	5,563	8,044
Other Assets	8,940	8,889	10,670	11,125	11,684	11,957	14,101	15,547	16,509	17,882
Total Assets	21,128	21,037	22,861	23,963	23,663	25,152	27,101	29,463	32,718	37,387

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	1,741	2,382	1,463	1,691	3,068	3,755	3,326	3,238	4,134	5,005
Cash from Investing Activity	-4,523	-1,310	-854	-1,669	104	-2,387	-1,872	-2,389	-2,988	-3,691
Cash from Financing Activity	3,104	-1,326	-385	-349	-2,949	-1,240	-1,600	-958	-1,200	-1,293
Net Cash Flow	322	-254	223	-326	224	129	-146	-109	-55	21

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	33.55%	33.47%	33.47%	33.47%	33.47%	30.91%	30.92%	29.19%	29.20%	29.19%	29.21%	29.21%
FIIs	27.41%	25.49%	25.74%	25.73%	25.83%	27.81%	28.80%	26.65%	26.28%	25.24%	24.54%	23.93%
DIIs	22.10%	24.34%	24.19%	24.34%	24.42%	24.95%	24.17%	27.72%	28.16%	29.26%	30.25%	30.73%
Public	16.94%	16.70%	16.60%	16.46%	16.28%	16.33%	16.11%	16.44%	16.37%	16.30%	15.99%	16.13%
Total Shareholders	4,75,293	4,66,513	4,26,861	4,25,731	4,36,154	4,63,569	4,70,234	5,25,114	5,43,420	5,49,655	5,34,587	5,40,521

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q2 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q1 FY25

Showing 1 - 8 of 40

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Cipla Ltd

Cipla Ltd (CIPLA) is currently trading at 1,334.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs). In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid. The company secured strategic distribution rights with Pfizer to expand its portfolio in the acute therapy segment, boosting its market presence and scalability. Cipla expanded its portfolio by acquiring Inzpera Healthsciences, enhancing its offerings in pediatric pharmaceuticals and wellness products. Cipla continues to lead in key therapeutic areas such as respiratory, anti-diabetes, and cardiac segments, fostering robust growth and competitive positioning.

Over the past 52 weeks, Cipla Ltd has traded between a low of ₹1,283.00 and a high of ₹1,672.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Cipla Ltd has a market capitalization of approximately 1,08,977.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Cipla Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.90 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,08,977.69 Cr, Cipla Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Cipla Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Cipla Ltd is 22.90. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The 'Biopharma Shakti' scheme is the most significant announcement. With a INR 10,000 crore outlay, it aims to make India a global biopharma hub, directly supporting Cipla's focus on biologics, biosimilars, and R&D.

The profit decline was primarily due to a one-time charge of ₹276 crore for new labour laws, lower sales from its gRevlimid product in the US market, and overall pressure on operating margins.

Cipla has a market capitalization of approximately ₹1.24 trillion (or ₹1,23,653 crore), classifying it as a large-cap stock in the Indian market.

Afrezza is a rapid-acting, orally inhaled insulin powder used to manage high blood sugar in adults with type 1 and type 2 diabetes. It serves as a needle-free alternative to traditional injectable insulin.

Cipla Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock Premium Features

Upgrade

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Cipla Ltd

What is Cipla Ltd share price today?

What does Cipla Ltd do?

What is the 52-week high and low of Cipla Ltd?

What is the market capitalization of Cipla Ltd?

Should I consider investing in Cipla Ltd stock?

Is Cipla Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Cipla Ltd belong to and why does it matter?

What is the PE ratio of Cipla Ltd?

What is the most significant announcement in Union Budget 2026 for Cipla?

Why did Cipla's net profit fall by 57% in Q3 FY26?

What is Cipla's current market capitalization?

What is Afrezza?

Utility

Company

Technicals

Documents

Forecasts

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Frequently Asked Questions about Cipla Ltd

What is Cipla Ltd share price today?

What does Cipla Ltd do?

What is the 52-week high and low of Cipla Ltd?

What is the market capitalization of Cipla Ltd?

Should I consider investing in Cipla Ltd stock?

Is Cipla Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Cipla Ltd belong to and why does it matter?

What is the PE ratio of Cipla Ltd?

What is the most significant announcement in Union Budget 2026 for Cipla?

Why did Cipla's net profit fall by 57% in Q3 FY26?

What is Cipla's current market capitalization?

What is Afrezza?

Announcements

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Peers

Price Chart Comparison

Overview